Sahussapont Joseph Sirintrapun, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathology, Clinical | 8 | 2021 | 376 | 2.670 |
Why?
|
| Pathology, Surgical | 5 | 2020 | 151 | 1.840 |
Why?
|
| Telepathology | 3 | 2020 | 77 | 1.470 |
Why?
|
| Pathology, Molecular | 2 | 2018 | 328 | 0.900 |
Why?
|
| Medical Informatics | 3 | 2021 | 732 | 0.860 |
Why?
|
| Kidney Neoplasms | 14 | 2024 | 4248 | 0.780 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2022 | 2223 | 0.700 |
Why?
|
| Research Report | 2 | 2019 | 367 | 0.630 |
Why?
|
| Peritoneal Neoplasms | 2 | 2016 | 711 | 0.630 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2024 | 148 | 0.630 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2020 | 517 | 0.590 |
Why?
|
| Informatics | 1 | 2018 | 72 | 0.590 |
Why?
|
| Carcinoma, Renal Cell | 10 | 2024 | 3163 | 0.530 |
Why?
|
| Cytological Techniques | 1 | 2018 | 218 | 0.530 |
Why?
|
| Parotid Neoplasms | 2 | 2013 | 157 | 0.490 |
Why?
|
| Appendix | 1 | 2014 | 109 | 0.430 |
Why?
|
| Electronic Health Records | 4 | 2021 | 4811 | 0.400 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 2022 | 782 | 0.390 |
Why?
|
| Cytophagocytosis | 1 | 2011 | 6 | 0.380 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 611 | 0.370 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2011 | 55 | 0.370 |
Why?
|
| Adenocarcinoma | 6 | 2022 | 6339 | 0.350 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 101 | 0.350 |
Why?
|
| Mesothelioma | 1 | 2016 | 807 | 0.350 |
Why?
|
| Carcinoma, Small Cell | 2 | 2022 | 420 | 0.340 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 716 | 0.340 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 549 | 0.330 |
Why?
|
| Carcinoma | 3 | 2019 | 2330 | 0.320 |
Why?
|
| Prostatic Neoplasms | 10 | 2022 | 11118 | 0.310 |
Why?
|
| ras Proteins | 1 | 2013 | 1053 | 0.300 |
Why?
|
| Specimen Handling | 3 | 2021 | 702 | 0.290 |
Why?
|
| Neoplasms | 10 | 2022 | 22164 | 0.290 |
Why?
|
| Urinary Bladder | 5 | 2022 | 1152 | 0.290 |
Why?
|
| Clinical Laboratory Information Systems | 2 | 2021 | 109 | 0.290 |
Why?
|
| Medical Oncology | 2 | 2021 | 2321 | 0.290 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2020 | 8999 | 0.280 |
Why?
|
| Microscopy | 3 | 2021 | 903 | 0.270 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 3687 | 0.270 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2019 | 194 | 0.260 |
Why?
|
| Prostate | 5 | 2022 | 1770 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 1051 | 0.250 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 3530 | 0.240 |
Why?
|
| Urothelium | 3 | 2019 | 269 | 0.240 |
Why?
|
| Immunohistochemistry | 10 | 2024 | 11073 | 0.240 |
Why?
|
| Prostatectomy | 4 | 2019 | 1824 | 0.230 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2022 | 339 | 0.230 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2024 | 44 | 0.230 |
Why?
|
| Ganglioneuroblastoma | 1 | 2023 | 10 | 0.220 |
Why?
|
| Tumor Burden | 2 | 2019 | 1890 | 0.210 |
Why?
|
| Computational Biology | 1 | 2015 | 3517 | 0.210 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 1179 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 7389 | 0.200 |
Why?
|
| Humans | 67 | 2024 | 761423 | 0.200 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2021 | 88 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2021 | 5879 | 0.180 |
Why?
|
| Social Control, Formal | 1 | 2021 | 108 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2020 | 70 | 0.180 |
Why?
|
| Telemedicine | 1 | 2018 | 3051 | 0.180 |
Why?
|
| Genomics | 7 | 2023 | 5820 | 0.180 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2021 | 161 | 0.170 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 1118 | 0.170 |
Why?
|
| Technology | 1 | 2022 | 292 | 0.170 |
Why?
|
| Papilloma, Inverted | 1 | 2019 | 19 | 0.170 |
Why?
|
| Ureteral Neoplasms | 1 | 2020 | 106 | 0.160 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2020 | 125 | 0.160 |
Why?
|
| DNA Copy Number Variations | 4 | 2021 | 2020 | 0.160 |
Why?
|
| Urologic Neoplasms | 2 | 2019 | 314 | 0.160 |
Why?
|
| Carcinoma, Medullary | 1 | 2019 | 115 | 0.160 |
Why?
|
| New York City | 1 | 2021 | 731 | 0.160 |
Why?
|
| Dog Diseases | 1 | 2019 | 141 | 0.160 |
Why?
|
| Ecosystem | 1 | 2023 | 490 | 0.150 |
Why?
|
| Science | 1 | 2021 | 239 | 0.150 |
Why?
|
| Kallikreins | 1 | 2019 | 220 | 0.150 |
Why?
|
| Workflow | 2 | 2020 | 851 | 0.150 |
Why?
|
| Cadherins | 2 | 2020 | 904 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 698 | 0.140 |
Why?
|
| Antibody Specificity | 1 | 2019 | 1060 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2019 | 318 | 0.140 |
Why?
|
| Pathology | 1 | 2020 | 270 | 0.140 |
Why?
|
| Telemetry | 1 | 2018 | 199 | 0.140 |
Why?
|
| Telomerase | 1 | 2021 | 745 | 0.130 |
Why?
|
| Efficiency | 1 | 2019 | 476 | 0.130 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 560 | 0.130 |
Why?
|
| Male | 35 | 2024 | 360736 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2019 | 2510 | 0.120 |
Why?
|
| Genome Components | 1 | 2014 | 5 | 0.120 |
Why?
|
| Burnout, Professional | 1 | 2024 | 704 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2023 | 1250 | 0.120 |
Why?
|
| Neurology | 1 | 2022 | 780 | 0.120 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2014 | 82 | 0.120 |
Why?
|
| NAD | 1 | 2018 | 614 | 0.120 |
Why?
|
| Databases, Factual | 4 | 2020 | 7956 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 8000 | 0.110 |
Why?
|
| Retrospective Studies | 15 | 2023 | 80582 | 0.110 |
Why?
|
| Epoxy Compounds | 1 | 2014 | 137 | 0.110 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 596 | 0.110 |
Why?
|
| Checklist | 1 | 2021 | 828 | 0.110 |
Why?
|
| Gene Dosage | 1 | 2018 | 1218 | 0.110 |
Why?
|
| Receptors, Androgen | 1 | 2020 | 1079 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 255 | 0.110 |
Why?
|
| Vesiculovirus | 1 | 2013 | 55 | 0.110 |
Why?
|
| Patient Participation | 1 | 2022 | 1444 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 2 | 2019 | 2469 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2022 | 4021 | 0.100 |
Why?
|
| Karyotyping | 1 | 2014 | 1171 | 0.100 |
Why?
|
| Aged | 19 | 2024 | 169235 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 931 | 0.100 |
Why?
|
| Lactones | 1 | 2014 | 317 | 0.100 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2012 | 35 | 0.100 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2013 | 306 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2020 | 1520 | 0.100 |
Why?
|
| Microarray Analysis | 1 | 2014 | 749 | 0.100 |
Why?
|
| Rhabdoid Tumor | 1 | 2013 | 210 | 0.090 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 2578 | 0.090 |
Why?
|
| Antibodies | 1 | 2019 | 2421 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2013 | 535 | 0.090 |
Why?
|
| Carcinoma, Papillary | 2 | 2019 | 785 | 0.090 |
Why?
|
| Gene Amplification | 3 | 2020 | 1088 | 0.090 |
Why?
|
| Teratoma | 1 | 2013 | 404 | 0.090 |
Why?
|
| Middle Aged | 21 | 2024 | 220826 | 0.090 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 15262 | 0.090 |
Why?
|
| Biopsy | 5 | 2021 | 6766 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 2057 | 0.080 |
Why?
|
| DNA Helicases | 1 | 2015 | 851 | 0.080 |
Why?
|
| Speech Recognition Software | 1 | 2010 | 74 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2020 | 4001 | 0.080 |
Why?
|
| Oncolytic Viruses | 1 | 2013 | 344 | 0.080 |
Why?
|
| Female | 21 | 2024 | 392581 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2013 | 1170 | 0.080 |
Why?
|
| Mutation | 7 | 2024 | 30045 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2014 | 1509 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 20093 | 0.070 |
Why?
|
| Oncolytic Virotherapy | 1 | 2013 | 516 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 3702 | 0.070 |
Why?
|
| Curriculum | 1 | 2021 | 3741 | 0.070 |
Why?
|
| Neuroendocrine Tumors | 1 | 2013 | 641 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3639 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 9277 | 0.070 |
Why?
|
| Pandemics | 3 | 2022 | 8641 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2018 | 3466 | 0.070 |
Why?
|
| Education, Medical | 1 | 2018 | 1725 | 0.070 |
Why?
|
| Neoplasm Staging | 5 | 2023 | 11106 | 0.070 |
Why?
|
| Disease Progression | 4 | 2018 | 13502 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6814 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6479 | 0.060 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 1175 | 0.060 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 1156 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5335 | 0.060 |
Why?
|
| Time Factors | 4 | 2019 | 39975 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 1192 | 0.060 |
Why?
|
| Prognosis | 4 | 2023 | 29620 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 2415 | 0.050 |
Why?
|
| Adult | 11 | 2024 | 221148 | 0.050 |
Why?
|
| Survivors | 1 | 2013 | 2371 | 0.050 |
Why?
|
| Isoflurane | 2 | 1996 | 384 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3082 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3202 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 6935 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2022 | 164 | 0.050 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2022 | 106 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 1420 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 9606 | 0.050 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 16979 | 0.050 |
Why?
|
| Cell Movement | 1 | 2013 | 5203 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2024 | 12970 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 3589 | 0.050 |
Why?
|
| Anesthetics, Inhalation | 2 | 1996 | 574 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5709 | 0.040 |
Why?
|
| Survival Rate | 1 | 2014 | 12720 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2020 | 101 | 0.040 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 58956 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2021 | 297 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2014 | 12796 | 0.040 |
Why?
|
| Adolescent | 4 | 2019 | 88313 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 1271 | 0.040 |
Why?
|
| Seminal Vesicles | 1 | 2019 | 103 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2021 | 347 | 0.040 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 83 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2811 | 0.040 |
Why?
|
| Chromosomes, Human, Y | 1 | 2019 | 161 | 0.040 |
Why?
|
| Ploidies | 1 | 2018 | 285 | 0.040 |
Why?
|
| Phenotype | 3 | 2022 | 16606 | 0.040 |
Why?
|
| United States | 6 | 2021 | 72339 | 0.040 |
Why?
|
| Cystectomy | 1 | 2022 | 634 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2014 | 3614 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 3812 | 0.030 |
Why?
|
| Chromosomes, Human, X | 1 | 2019 | 321 | 0.030 |
Why?
|
| Acrylamides | 1 | 2018 | 259 | 0.030 |
Why?
|
| Risk Assessment | 4 | 2019 | 23990 | 0.030 |
Why?
|
| Histone Demethylases | 1 | 2019 | 320 | 0.030 |
Why?
|
| Mexico | 1 | 2018 | 763 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 2914 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 3602 | 0.030 |
Why?
|
| Tretinoin | 1 | 2018 | 519 | 0.030 |
Why?
|
| Anesthesia, Inhalation | 1 | 1996 | 220 | 0.030 |
Why?
|
| Patient Care | 1 | 2021 | 621 | 0.030 |
Why?
|
| Phylogeny | 1 | 2022 | 2811 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1996 | 246 | 0.030 |
Why?
|
| Dogs | 1 | 2019 | 3839 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2019 | 1511 | 0.030 |
Why?
|
| Mitosis | 1 | 2019 | 1187 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2022 | 2555 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2022 | 3514 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2022 | 1410 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11740 | 0.030 |
Why?
|
| Metabolism | 1 | 2014 | 193 | 0.030 |
Why?
|
| Women's Health | 1 | 2022 | 2065 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 2605 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 9418 | 0.030 |
Why?
|
| Evoked Potentials, Motor | 1 | 1996 | 464 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1664 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1771 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2013 | 196 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2019 | 1742 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2020 | 1126 | 0.020 |
Why?
|
| Interferon-beta | 1 | 2013 | 345 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2018 | 1607 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 2760 | 0.020 |
Why?
|
| ROC Curve | 1 | 2019 | 3580 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 2826 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2018 | 10441 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2021 | 2220 | 0.020 |
Why?
|
| Medical Records Department, Hospital | 1 | 2010 | 6 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2018 | 1808 | 0.020 |
Why?
|
| Transfection | 1 | 2018 | 5775 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 1893 | 0.020 |
Why?
|
| Random Allocation | 1 | 2014 | 2394 | 0.020 |
Why?
|
| Piperidines | 1 | 2018 | 1656 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2018 | 3779 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 2916 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2824 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 1626 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 2230 | 0.020 |
Why?
|
| Motor Cortex | 1 | 1996 | 1006 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2013 | 621 | 0.020 |
Why?
|
| Animals | 7 | 2019 | 168441 | 0.020 |
Why?
|
| Spinal Cord | 1 | 1996 | 1818 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 5789 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2021 | 64651 | 0.020 |
Why?
|
| Lipids | 1 | 2018 | 3340 | 0.020 |
Why?
|
| Patient Selection | 1 | 2019 | 4244 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 2918 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 17912 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 3356 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 1902 | 0.020 |
Why?
|
| Gene Expression | 1 | 2018 | 7584 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 12058 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 39117 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 3623 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5305 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2019 | 6581 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 3712 | 0.010 |
Why?
|
| Cytokines | 1 | 2018 | 7392 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2010 | 1400 | 0.010 |
Why?
|
| Mice | 3 | 2015 | 81509 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2013 | 8320 | 0.010 |
Why?
|
| Young Adult | 2 | 2019 | 59207 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 3081 | 0.010 |
Why?
|
| Risk Factors | 2 | 2019 | 74167 | 0.010 |
Why?
|
| Child | 2 | 2019 | 80162 | 0.010 |
Why?
|
| Infant | 1 | 2023 | 36205 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2014 | 23441 | 0.010 |
Why?
|
| SEER Program | 1 | 2005 | 1450 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1996 | 5776 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2005 | 937 | 0.010 |
Why?
|
| Algorithms | 1 | 2020 | 14026 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2015 | 18964 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15941 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2011 | 2752 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 14664 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 22168 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1996 | 8179 | 0.010 |
Why?
|
| Blood Pressure | 2 | 1996 | 8487 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 1996 | 1037 | 0.010 |
Why?
|
| Rats | 2 | 1996 | 23742 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 36423 | 0.000 |
Why?
|
| Respiration, Artificial | 1 | 1996 | 2625 | 0.000 |
Why?
|